News summary

Onward Therapeutics Closes NT$900 Million (approximately US$28 Million) Series B Financing to Advance Clinical-Stage Oncology Pipeline

Source: PR Newswire • Published: 17 Nov 2026, 23:00

Summarized by Masters of Longevity from PR Newswire.

Company closed NT$900 million Series B to fund clinical oncology programs.

Onward Therapeutics Closes NT$900 Million (approximately US$28 Million) Series B Financing to Advance Clinical-Stage Oncology Pipeline
Key Takeaways
  • Onward Therapeutics raised NT$900 million for clinical programs.
  • OT-A201 showed preliminary tumor responses with manageable safety.
  • OT-C001 reported favorable safety and several complete responses.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.MoL PickMOTS-c: Where the Evidence EndsStudies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?